Reviewer's report

Title: Phase II Study of the Combination Carboplatin plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients

Version: 3 Date: 26 December 2010

Reviewer: Filippo Bellati

Reviewer's report:

Dear Editor,

thank you for asking me to review the interesting manuscript “Phase II Study of the Combination Carboplatin plus Celecoxib in Heavily pre-treated Recurrent Ovarian Cancer Patients” written by Legge F. et al.

The paper evaluates the antitumor activity and safety of this combination, focusing on the advantages of the target therapy.

The potential changes induced by the experimental target therapy on angiogenesis-related serum markers and quality of life were also evaluated.

I suggest to mention a similar experience concerned in changes of immunological setting and a related improvement of QoL, induced by targeting VEGF, recently reported by Bellati et al. (Invest New Drugs. 2010). Both novel strategies aimed at increasing platinum sensitivity in recurrent resistant/refractory ovarian cancer patients.

The topic of the manuscript is of high interest for gynecologic oncologists.

Overall the manuscript is well written, arguments are supported by data, findings are novel and relevant for possible future assessment of standard of care.

Statistical analyses have been conducted properly.

Tables and figures are detailed but simple to consult.

I think the manuscript is appropriate and innovative for publications in Gynecologic Oncology presenting at least an incremental advance over previously published work.

For these reasons, we also think that it is certainly in scope for the journal.

Globally, in my opinion this manuscript could be accepted with Discretionary Revisions

Level of interest: An article of outstanding merit and interest in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.